Nordic Pharma

icon box image

Corporate functions :

Paris, France​
Amsterdam, Netherlands

icon box image

Year of incorporation :

1995

icon box image

Number of employees :

460

icon box image

Production Footprint :

Farmaprim​ (Moldova)​

A focus on niche products means expertise in rheumatology, critical care and women’s health

Nordic Group is a privately owned international pharmaceutical company with a presence in 17 countries. It focuses on the development and commercialisation of a wide variety of products to respond to unmet medical needs. Nordic Group expertise relies on the development and sales of its own products, but also on partner products acquired at various stages of development. Its portfolio of therapeutic areas includes rheumatology, women’s health and critical care.

Strengths

Nordic Pharma is a medium-size pharmaceutical company, with an impressive history of acquisitions and internal product development. It focuses on the development of many products in rheumatology, critical care and women’s health.

Nordic Pharma has a wide reach across all Europe, with a presence in 17 countries.

Nordic Pharma’s emphasis on rheumatology is exemplified by its ‘Nordimet Pen’, which treats rheumatism and arthritis. Nordimet Pen administers the drug Methotrexate safely, reliably, and above all, highly effectively. Nordimet Pen is a single dose auto-injector, which means that patients can administer it themselves without support from a nurse. Nordic Pharma also has a strong track record in women’s health. In this regard, one of its major products is Mifepristone, which combined with Misoprostol, allows for the safe and early termination of pregnancy. Mifepristone is also self-administered and has significant benefits when compared to surgical termination of pregnancy.

Critical care is Nordic Pharma’s third, and fast developing, therapeutic area. Critical care encompasses oncology products such as Teysuno for the treatment of gastric cancer, cardiac surgery products such as Trasylol, as well as anaesthesiology and orphan drugs such as Amglidia for postnatal diabetes.

Business type​:

B2C and B2B Pharmaceutical company which produces and commercializes both promoted products and generics

Core treatment areas

  • Rheumatology
  • Haematology
  • Gynaecology
  • Oncology
  • Anaesthesia
  • Neonatal diabetes

Capabilities​:

Development

Manufacturing

Commercial

Registration / Safety Monitoring

Market Access

Life Cycle Management

Technology

Tablets, injections, creams, suppositories, ovules,​ medical devices

Company commercial footprint

  • Corporate functions
  • Commercial footprint
  • Manufacturing footprint

  • Corporate functions
  • Commercial footprint
  • Manufacturing footprint
  • Corporate functions
  • Commercial footprint
  • Manufacturing footprint

  • Corporate functions
  • Commercial footprint
  • Manufacturing footprint

  • Corporate functions
  • Commercial footprint
  • Manufacturing footprint
map-sever-full
map-nordic-pharma-1
map-amring
Map-izvarino
Sever-solution-map-v3
  • Corporate functions
  • Commercial footprint
  • Manufacturing footprint

Other company profiles